The pace of innovation is accelerating as healthcare IT vendors look to integrate artificial intelligence into their offerings for provider operations, medical testing, patient engagement, and other use cases.
Aspira Women’s Health, Belong.life, and Outbound AI are just three companies to announce new AI-driven technologies to support advanced ovarian cancer detection, cancer patient engagement, and claims management, respectively.
AI virtual agent for billing
Seattle-based Outbound AI, which was founded in 2021, announced Tuesday that it has augmented its cloud-based PayerVA console with generative AI that “augments human talent” while reducing the burden on claims professionals.
The company said its mission is to create tools that ease the administrative burden across the healthcare revenue cycle, reduce administrative costs, increase productivity, and improve the “everyday work experience.” there is
“The amount of time medical claims teams are spending on the phone with payers is truly staggering,” Outbound AI founder and CEO Stead Burwell said in a statement.
“You can easily spend two-thirds of your day at work, which is counterproductive and reduces job satisfaction and performance,” he says.
According to Outbound AI, PayerVA’s virtual agents operate the payer’s automated voice response system, wait on hold, and converse with human representatives. They take “comprehensive notes” and leverage GPT to create descriptive summaries of calls and transactions.
“Our AI virtual agents are specially trained to handle routine phone-based tasks, enabling human resources to be more strategic and get more work done.” Burwell said.
Jonathan Wiggs, co-founder and CTO of a Madrona Venture Lab-incubated startup, says generative AI agents simulate how experienced claims team members create narratives and adhere to the same standards. explained that
“We are not only leveraging the power of GPT, but we are doing so in a highly secure and HIPAA compliant way through Microsoft Azure,” he added.
“This is very important for any company serving the healthcare industry, especially considering the HIPAA-mandated business partnership agreement is not available, especially when using GPT directly via OpenAI.”
Since the launch of our billing platform, we have added a series of new features including pre-approval and rejection management.
miRNA-based cancer diagnosis
Ovarian cancer has historically been very difficult to diagnose and is therefore very deadly.
Aspira Women’s Health has partnered with the Boston-based Dana-Farber Cancer Institute to develop a non-invasive miRNA-based approach that utilizes circulating microRNAs alone or in combination with proteins and other factors to identify the ovaries. entered into an exclusive license agreement for the design and development of tests for Cancer in women with adnexal masses.
“The addition of this new non-invasive, molecular-based risk assessment tool to our portfolio will be another major step forward in providing physicians with the information they need to decide on the appropriate treatment route.” President and CEO Nicole Sandford said in the announcement on Thursday.
The new test will become part of the company’s ovarian cancer risk assessment portfolio, according to the company, and is a non-invasive, blood-based test for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses. It will be a combination of testing with the FDA. – A clear product to detect the risk of ovarian malignancies scheduled for surgery.
Dipanjan Chowdhury, co-founder and head of the Radiation and Genomic Stability Division at DFCI, said, “This technology is a non-invasive, easy, rapid, and affordable diagnosis that can help reduce the risk of cancer in ovarian cancer. It could help address unmet diagnostic needs.”
Customizable AI Oncology Mentor
According to Belong.Life, a patient engagement and community platform, Dave will provide a new level of support for cancer patients and their families.
“Dave, Belong’s lead in AI oncology, marks an important milestone in our commitment to revolutionize the healthcare industry,” co-founder and CEO Eliran Malki said in a statement Wednesday. increase.
“Dave can deliver smart, personalized, and accessible information instantly to significantly improve the care and quality of life for millions of patients around the world.”
Dave also uses natural language processing trained on patient-physician and patient-to-patient interaction data aggregated from Belong’s Beating Cancer Together app and tested by over 10,00 cancer patients at scale. language model.
We can provide oncology-specific, comprehensive and empathetic answers to cancer patient challenges. According to the company, Dave also retains long-term memory of previous interactions, allowing for ongoing communication across multiple chat sessions of his.
It is available free to users on Belong’s Beating Cancer Together app and as a customizable SaaS solution for hospitals, healthcare providers and patient support programs. Providers may include internal clinical guidelines for optimal and exclusive use.
Andrea Fox is senior editor for Healthcare IT News.
Email: afox@himss.org
Healthcare IT News is a HIMSS Media publication.
